Receptor Life Sciences Receives FDA Guidance for Development of RLS 103, Designed for the Treatment of Acute Panic Attack
“Alignment on a clear 505(b)(2) development pathway for RLS103 is a significant milestone for the company,” said Andrea Leone-Bay, PhD, Chief Scientific Officer of RLS. “Currently no immediate-acting products are available for panic attacks, so RLS103 has the potential to be First-in-Class. We look forward to continuing our dialogue with the FDA and have initiated our IND-enabling studies.”
Panic disorder affects approximately 5.4 million adults (2.7% of the population) in the U.S., according to the National Institute of Mental Health. Benzodiazepines are the most common treatment for panic despite their well-known undesirable side effects, including dependence, sedation, and tolerance. An inhaled CBD formulation holds the potential to treat panic in a safe, effective, and convenient manner.
RLS103 is a drug-device combination product based on the Technosphere® dry powder inhalation system licensed from MannKind Corporation.
The FDA’s 505(b)(2) pathway was established in 1984 to accelerate the development of promising new medications by allowing the use of data based on previously approved drugs.
About Receptor Life Sciences
Receptor Life Sciences is a pharmaceutical company that applies FDA-approved drug-delivery technologies to develop innovative therapies to address central nervous system disorders that have few safe and effective treatments. Receptor Life Sciences uses these technologies to produce inhaled and oral cannabinoid products that hold the potential to provide precision, consistency, reliability, and convenience. For more information about Receptor Life Sciences, its patented product candidates and its progress toward FDA approval see: www.ReceptorLife.com.
Source: Receptor Life Sciences